Karachi, December 3, 2024 – Citi Pharma Limited has announced a landmark partnership with Mersi Farma, a leading pharmaceutical company based in Indonesia, to advance Active Pharmaceutical Ingredient (API) manufacturing and expand the nutraceutical market in Indonesia.
This strategic collaboration, formalized through a Memorandum of Understanding (MoU) shared with the Pakistan Stock Exchange (PSX) on Tuesday, aims to transform Indonesia’s pharmaceutical landscape while addressing its healthcare needs.
Key Highlights of the Partnership
1. Establishing Cutting-Edge API Manufacturing Facilities
The collaboration includes the development of state-of-the-art API manufacturing plants in Indonesia:
• Paracetamol API Plant: An advanced facility with an annual production capacity of 10,000 metric tons.
• Amoxicillin API Plant: A high-capacity plant capable of producing 1,800 metric tons annually.
Both facilities will adhere to Pharmaceutical Inspection Co-operation Scheme (PIC/S) compliance standards, ensuring global benchmarks in quality. These will be the first large-scale API manufacturing plants in Indonesia, reducing the country’s reliance on imported APIs and significantly bolstering local production capabilities.
2. Joint Investment and Expertise Integration
Citi Pharma will contribute significant capital and cutting-edge technology to establish world-class production facilities. Meanwhile, Mersi Farma will leverage its deep market expertise and operational network within Indonesia to manage the distribution and optimization of APIs, ensuring seamless market penetration.
3. Expanding the Nutraceutical Market
Citi Pharma will launch its premium nutraceutical product line, addressing Indonesia’s growing demand for health and wellness products. Mersi Farma will lead the marketing, sales, and distribution efforts through its robust local channels.
Strategic Implications
This partnership is poised to:
• Drive innovation in pharmaceutical and nutraceutical manufacturing.
• Enhance Indonesia’s healthcare accessibility through localized API production.
• Promote economic sustainability by reducing dependency on imported APIs and fostering industrial growth.
Looking Ahead
With Indonesia’s first large-scale API production facilities, this collaboration sets a new standard for self-reliance and healthcare innovation. Citi Pharma and Mersi Farma are committed to achieving milestones that showcase excellence in pharmaceutical production and distribution. Updates on the progress and achievements of this transformative partnership will follow.